on Jaguar Health, Inc. (NASDAQ:JAGX)
Jaguar Health Releases Q3 2026 Financial Results
Jaguar Health, Inc., based in San Francisco, has announced its consolidated financial results for the third quarter of 2026. The company's license and grant revenue saw a significant increase, attributed to a U.S. commercial licensing agreement with Woodward Specialty, LLC for Mytesi® and Canalevia®-CA1. However, total net revenue from prescription products decreased by 81.9% compared to the previous year, with net revenue at $0.5 million. This shift aligns with Jaguar's strategic focus on developing a powder-for-oral-solution formulation of crofelemer for rare diseases.
Operational costs showed a decline, reflecting a $1.2 million decrease in loss from operations. Net loss also improved, decreasing by $3.8 million. The company's decision to focus on research and development and reduce operational expenses has impacted their financial standing positively. Despite lower revenue, the reduction in costs offered stability amid strategic transitions.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Jaguar Health, Inc. news